Efficacy and safety of switching basal insulin to insulin glargine 300 U/ mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study
Authors' conclusion
Switching BI to Gla-300 from a BOTplus or MDI regimen with prior insulin Gla-100, IDeg, IDet, or NPH improved glycaemic control in participants with inadequately controlled T2DM over 12 months without increasing hypoglycaemia risk or weight gain.
Study context
- Population
- Adults (≥18 years) with T2DM, HbA1c 7.5%–10.0% and fasting plasma glucose (FPG) >130 mg/dL (>7.2 mmol/L) on BOTplus or MDI, Germany582 completed 12 months
- Participants
- 1,217 adults
- Exposure
- Switch of basal insulin to Gla-300 from BOTplus or MDI regimen
- Outcome
- Duration of glycaemic target achievement: time between ≥2 FPG values ≤110 mg/dL (≤6.1 mmol/L) or ≥1 HbA1c value below predefined target
- Follow-up
- 12 months
Methodological detailsnon-interventional, multicentre, open-label, real-world, 12-month
- Non-interventional
- Multicentre
- Open-label
- Real-world
- 12-month
Main finding
As reported in the abstract
Gla-300
48.1%
280 events
- Median response duration
- 295 days (95% CI: 226, 381)
Observational data: associations, not effects.
Further findings
Change in HbA1c from baseline · month 12
- Mean (±SD) change in HbA1c from baseline (n = 568)
- −0.56% (±1.08)
- P value
- P < 0.0001
Change in FPG from baseline · month 12
- Mean (±SD) change in FPG from baseline (n = 540)
- −29.3 mg/dL or 1.63 mmol/L (±54.95)
- P value
- P < 0.0001
Safety
- Numbers and incidence of hypoglycaemia similar before Gla-300 and at month 12
Original publication
Efficacy and safety of switching basal insulin to insulin glargine 300 U/ mL in individuals with inadequately controlled type 2 diabetes on advanced insulin therapies: The Toujeo‐Neo T2DM study. Diabetes Obes Metab. Published 20 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →